Volume 121, Issue 5 , Pages 1219-1224, May 2008
Correlation of serum allergy (IgE) tests performed by different assay systems
Background
In vitro testing is commonly used to diagnose and manage allergies. Clinical reactivity has been correlated with food-specific IgE levels by using the ImmunoCAP (Phadia, Uppsala, Sweden).
Objective
To determine whether IgE levels derived from different assays are equivalent to those measured by ImmunoCAP.
Methods
Fifty patients from the Mount Sinai Pediatric Allergy practice were prospectively enrolled. For each deidentified sample, specific IgE levels were measured to egg, milk, peanut, cat, birch, and Dermatophagoides farinae at different laboratories, each using a different assay system (Phadia ImmunoCAP, Agilent Turbo-MP, and Siemens Immulite 2000). Results were analyzed to determine whether IgE measurements were equivalent. Food allergen–specific IgE levels were correlated with clinical data and around empirically determined thresholds that predict probability of clinical disease in 50% or 95% of subjects.
Results
Variable degrees of agreement existed among the 3 assays. Immulite 2000 overestimated all specific IgE levels compared with ImmunoCAP. Turbo-MP overestimated for egg but underestimated for birch and D farinae. Differences for milk, peanut, and cat were observed, without a trend toward overestimation or underestimation. Furthermore, several values for the food allergens were discrepant around the 50% and 95% positive predictive values for clinical reactivity.
Conclusion
Discrepancies in specific IgE values from 3 different assays can potentially lead to altered management and treatment. The predictive values for clinical reactivity associated with food-specific IgE levels determined by ImmunoCAP should not be applied to results from other assays.
Key words: Allergens, IgE, ImmunCAP, Turbo-MP, Immulite, food allergy
Abbreviations used: 50PPV, 50% Positive predictive value for clinical reactivity, 95PPV, 95% Positive predictive value for clinical reactivity
All costs for the laboratory analysis were covered by Phadia AD, Uppsala, Sweden.
Disclosure of potential conflict of interest: J. Wang has received research support from Phadia. H. A. Sampson has consulting arrangements with Allertein and has received research support from Phadia and the National Institutes of Health. J. H. Godbold has declared that he has no conflict of interest.
PII: S0091-6749(07)03577-4
doi:10.1016/j.jaci.2007.12.1150
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 5 , Pages 1219-1224, May 2008
